Status:
TERMINATED
TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Conditions:
Critical Illness
Enteral Nutrition
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the treatment effect of intravenous TAK-954 in improving the average daily protein adequacy received through enteral nutrition in critically-ill participants dev...
Detailed Description
The drug being tested in this study is called TAK-954. The study will assess the treatment effect of intravenous TAK-954 in improving average daily protein adequacy received through enteral nutrition ...
Eligibility Criteria
Inclusion
- Has at least a size 12-(french size) Fr nasogastric or orogastric tube with its tip at least 10 centimeter (cm) below the esophagogastric junction confirmed radiologically (the tip of the tube must be in the body or the antrum of the stomach and not in the fundus).
- Is intubated and mechanically ventilated in the ICU.
- Is expected to remain alive, mechanically ventilated, and receive continuous enteral feeding for \>=48 hours following randomization.
- Have EFI, defined as a single GRV measurement of \>=250 mL with vomiting/retching within the last 24 hours, or a single GRV measurement of \>=500 mL with or without vomiting/retching within the last 24 hours.
Exclusion
- Is under consideration for withdrawal of life-sustaining treatments within the next 72 hours.
- Has had major esophageal or gastric surgery or direct luminal trauma on this admission (participants with lower abdominal surgery are not excluded unless enteral feeding is contraindicated).
- Has mechanical bowel obstruction, short bowel syndrome, or the presence of an active gastric pacemaker.
- Have pre-existing hepatic disease that meets Child-Pugh Class B (moderate; total score 7 to 9 points) or C (severe; total score 10 to 15 points).
- Has been admitted primarily for treatment of a drug overdose.
- Has a presence of a post-pyloric tube in place at Randomization that may be used for enteral nutrition.
- Is receiving parenteral nutrition (PN) at Screening.
- Is in diabetic ketoacidosis or non-ketotic hyperosmolar coma.
- Has a different nutrient requirement than allowed in feeding protocol.(outside a range of 1.2 to 2 gram per kilogram per day \[g/kg/day\] of proteins and up to 1.5 kilocalorie per milliliter \[kcal/mL\]).
Key Trial Info
Start Date :
August 25 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 29 2018
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03477903
Start Date
August 25 2018
End Date
August 29 2018
Last Update
September 24 2019
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Joseph M Still Burn Centers
Augusta, Georgia, United States, 30909
2
Eastern Idaho Medical Consultants
Idaho Falls, Idaho, United States, 83404
3
Illinois Lung & Critical Care Institute
Peoria, Illinois, United States, 61606
4
University of Kentucky Health Care
Lexington, Kentucky, United States, 40536